## General Information

<table>
<thead>
<tr>
<th>Protocol</th>
<th>Real World Evidence of the Effectiveness of Paritaprevir/r – Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients with Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)</th>
</tr>
</thead>
</table>
18 December 2017                                                                                                                             |
| Related Documents                 | Study Protocol, dated 17 November 2016                                                                                                                                                          |
| Document owner                    | IST GmbH, Soldnerstrasse 1, D-68219 Mannheim                                                                                                                                                   |
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. INTRODUCTION</td>
<td>8</td>
</tr>
<tr>
<td>2. STUDY OBJECTIVES</td>
<td>9</td>
</tr>
<tr>
<td>3. STUDY DESIGN</td>
<td>9</td>
</tr>
<tr>
<td>3.1 Overview of Study Design and Dosing Regimen</td>
<td>9</td>
</tr>
<tr>
<td>3.2 Sample Size Calculation</td>
<td>10</td>
</tr>
<tr>
<td>4. STATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN</td>
<td>11</td>
</tr>
<tr>
<td>4.1 Primary and Secondary Parameters</td>
<td>11</td>
</tr>
<tr>
<td>4.1.1 Primary Effectiveness Parameter</td>
<td>11</td>
</tr>
<tr>
<td>4.1.2 Secondary Parameters</td>
<td>11</td>
</tr>
<tr>
<td>4.2 Statistical and Analytical Methods</td>
<td>12</td>
</tr>
<tr>
<td>4.2.1 Analysis Populations and Analysis Groups</td>
<td>12</td>
</tr>
<tr>
<td>4.2.2 Definition of Baseline and Visit Time Windows</td>
<td>17</td>
</tr>
<tr>
<td>4.2.3 Handling of missing data</td>
<td>20</td>
</tr>
<tr>
<td>4.2.4 Site and Researcher Information</td>
<td>21</td>
</tr>
<tr>
<td>4.2.5 Patient Disposition</td>
<td>22</td>
</tr>
<tr>
<td>4.2.6 Baseline Characteristics</td>
<td>23</td>
</tr>
<tr>
<td>4.2.6.1 Socio-demographic characteristics</td>
<td>23</td>
</tr>
<tr>
<td>4.2.6.2 CHC disease characteristics</td>
<td>24</td>
</tr>
<tr>
<td>4.2.6.3 CHC treatment history</td>
<td>25</td>
</tr>
<tr>
<td>4.2.6.4 Co-morbidities and co-infections</td>
<td>25</td>
</tr>
<tr>
<td>4.2.6.5 CHC related and other laboratory data at baseline</td>
<td>26</td>
</tr>
<tr>
<td>4.2.7 Analyses of the Objectives</td>
<td>29</td>
</tr>
<tr>
<td>4.2.7.1 Primary Effectiveness Variable</td>
<td>29</td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
</tr>
<tr>
<td>---------</td>
<td>-------</td>
</tr>
<tr>
<td>4.2.7.2</td>
<td>Secondary Variables</td>
</tr>
<tr>
<td>4.2.8</td>
<td>Analyses of Safety</td>
</tr>
<tr>
<td>4.2.8.1</td>
<td>Exposure to Study Medication</td>
</tr>
<tr>
<td>4.2.8.2</td>
<td>Co-medication</td>
</tr>
<tr>
<td>4.2.8.3</td>
<td>Adverse Events</td>
</tr>
<tr>
<td>4.2.8.4</td>
<td>Laboratory Data</td>
</tr>
<tr>
<td>4.2.9</td>
<td>Interim Analyses</td>
</tr>
<tr>
<td>4.2.9.1</td>
<td>First Interim Analysis</td>
</tr>
<tr>
<td>4.2.9.2</td>
<td>Second Interim Analysis</td>
</tr>
<tr>
<td>4.2.9.3</td>
<td>Third Interim Analysis</td>
</tr>
<tr>
<td>4.2.9.4</td>
<td>Fourth Interim Analysis</td>
</tr>
<tr>
<td>4.2.9.5</td>
<td>Fifth Interim Analysis</td>
</tr>
<tr>
<td>4.2.10</td>
<td>Protocol Violations and Deviations</td>
</tr>
<tr>
<td>5</td>
<td>DATA QUALITY ASSURANCE</td>
</tr>
<tr>
<td>6</td>
<td>METHODS OF DATA ANALYSIS AND PRESENTATION</td>
</tr>
<tr>
<td>6.1</td>
<td>Analysis Data Sets</td>
</tr>
<tr>
<td>6.2</td>
<td>SAS Output Format</td>
</tr>
<tr>
<td>7</td>
<td>REFERENCES</td>
</tr>
</tbody>
</table>
### GLOSSARY OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>APRI</td>
<td>AST to platelet ratio index</td>
</tr>
<tr>
<td>AFP</td>
<td>alfa fetoprotein</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine-aminotransferase</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate-aminotransferase</td>
</tr>
<tr>
<td>ANCOVA</td>
<td>analysis of covariance</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>BMQ</td>
<td>beliefs medication questionnaire</td>
</tr>
<tr>
<td>CA</td>
<td>competent authority</td>
</tr>
<tr>
<td>CD4</td>
<td>cluster of differentiation 4</td>
</tr>
<tr>
<td>CHC</td>
<td>chronic hepatitis C</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CNI</td>
<td>calcineurin</td>
</tr>
<tr>
<td>CP</td>
<td>core population</td>
</tr>
<tr>
<td>CPFSU</td>
<td>core population with sufficient follow-up data</td>
</tr>
<tr>
<td>CT</td>
<td>computer tomography</td>
</tr>
<tr>
<td>DAA</td>
<td>direct-acting antiviral agent</td>
</tr>
<tr>
<td>DDI</td>
<td>drug-drug interaction</td>
</tr>
<tr>
<td>EC</td>
<td>ethics committee</td>
</tr>
<tr>
<td>EDC</td>
<td>electronic data capture</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic case report form</td>
</tr>
<tr>
<td>EMA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>EoT</td>
<td>end of treatment</td>
</tr>
<tr>
<td>EQ-5D-5L</td>
<td>EuroQol 5 dimension 5 level</td>
</tr>
<tr>
<td>FACIT-Fatigue</td>
<td>Functional Assessment of Chronic Illness Therapy-Fatigue</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>FIB-4</td>
<td>Fibrosis-4 Score/Index</td>
</tr>
<tr>
<td>γ-GT</td>
<td>gamma-glutamyltransferase</td>
</tr>
<tr>
<td>HCC</td>
<td>hepatocellular carcinoma</td>
</tr>
<tr>
<td>HCP</td>
<td>health care provider</td>
</tr>
<tr>
<td>Hb</td>
<td>hemoglobin</td>
</tr>
<tr>
<td>HbA1c</td>
<td>hemoglobin A1c</td>
</tr>
</tbody>
</table>
GLOSSARY OF ABBREVIATIONS

HBV   hepatitis B virus
HCV   hepatitis C virus
HDL   high-density lipoprotein
HIV   human immunodeficiency virus
HOMA  homeostasis model assessment
HVPG  hepatic venous pressure gradient
ICMJE International Committee of Medical Journal Editors
IEC/IRB independent ethics committee/- review board
IgA   Immunoglobulin A
IgG   Immunoglobulin G
IgM   Immunoglobulin M
INN   international non-proprietary name
INR   international normalized ratio
LDL   low-density lipoprotein
LLoD  lower limit of detection
LLoQ  lower limit of quantification
MAH   Marketing Authorization Holder
MedDRA Medical Dictionary for Regulatory Activities
MLR   multiple logistic regression
MRI   magnetic resonance imaging
NCP   non-core population
NS3/NS4A nonstructural protein 3/nonstructural protein 4A
NS5A   nonstructural protein 5A
NS5B   nonstructural protein 5B
OATP  organic anion-transporting polypeptide
OLT   orthotopic liver transplant
PAM-13 Patient Activation Measure 13
paritaprevir/r paritaprevir/ritonavir
PCR   polymerase chain reaction
pegIFN pegylated interferon
PRISM Pictorial Representation of Illness and Self-Measure
PRO   patient reported outcome
PT    preferred term
GLOSSARY OF ABBREVIATIONS

RBV     ribavirin
RF      rheumatoid factor
RNA     ribonucleic acid
SAE     serious adverse event
SAP     statistical analysis plan
SD      standard deviation
SDP     study designated physician
SNP     single nucleotide polymorphism
SOC     system organ class
SP      safety population
SVR     sustained virological response
SVR12   SVR at 12 weeks after EoT
SVR24   SVR at 24 weeks after EoT
SVR48   SVR at 48 weeks after EoT
TAI     total activity impairment
TP      target population
TWP     total work productivity impairment
VAS     visual analogue scale
WHO     World Health Organization
WPAI    work productivity and activity impairment
WPAI-GH WPAI as general health measure
WPAI-SHP WPAI modified for specific health condition
1 Introduction

The interferon-free combination regimen of paritaprevir/r and ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well controlled conditions.

The rationale for this observational study is to determine how the efficacy and safety of the ABBVIE REGIMEN as demonstrated in pivotal trials translates into real world everyday clinical settings, which means evaluating its effectiveness. Whereas efficacy can be defined as a measure of the capacity of a treatment to produce the desired effect in a controlled environment, such as in a randomized controlled trial, effectiveness is the extent to which a drug achieves its intended effect in the usual clinical setting. Effectiveness trials typically have limited exclusion criteria and will involve the broader patient populations in routine clinical practice, treated per local label, which might include patients with heterogeneous compliance patterns and patients with significant comorbid conditions and could be used to model and disseminate best practices. Effectiveness research allows for external patient-, provider-, and system-level factors and can therefore be more relevant for health-care decisions by both providers in practice and policymakers.

This observational study is the first effectiveness research examining the ABBVIE REGIMEN ± RBV, used according to local label, under real world conditions in Germany in a clinical practice patient population. During the last decade, when dual therapy with pegylated interferon (pegIFN) plus RBV was standard of care for the treatment of CHC, the discovery of predictive factors for virological response and the subsequent development of treatment algorithms marked a milestone in patient care for CHC. As a consequence, treatment could be effectively targeted to patients most likely to respond. Interestingly, many of the now well established predictors of response to pegIFN/RBV and first generation direct acting antivirals (DAAs) in combination with pegIFN/RBV were not predictive of outcome in the development trials of the ABBVIE REGIMEN ± RBV. This observational study may play an important part in bridging the data gaps. It may help identify predictive factors of response that are important in real world treatment settings and thus, could assist in further optimizing treatment with the interferon-free ABBVIE REGIMEN ± RBV in the future.

The label of the ABBVIE REGIMEN ± RBV will vary according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease. It is therefore relevant to understand the pattern of use and outcome in daily clinical practice. In addition, this study will provide data on the impact of adherence on treatment outcomes in everyday settings, which may help treating physicians to improve the management of patients under their care.

The main aim of this observational study is to provide evidence of the effectiveness of the ABBVIE REGIMEN ± RBV in a real world setting across clinical practice patient populations.
2 Study Objectives

The objectives of this study are:

Primary objective:

1. To describe in routine clinical practice the effectiveness of the interferon-free ABBVIE REGIMEN ± RBV in patients with CHC as evidenced by sustained virological response at 12 weeks after end of treatment (SVR12)

Secondary objectives:

2. To provide real world evidence for predictive factors of virological response
3. To describe the pattern of real world use of the ABBVIE REGIMEN ± RBV with respect to different patient and treatment characteristics
4. To evaluate the influence of adherence on treatment outcome in routine clinical practice
5. To collect information on co-morbidities and concomitant medication in the German population
6. To describe the tolerability of the ABBVIE REGIMEN ± RBV
7. To document the effect of the ABBVIE REGIMEN ± RBV on PROs and work productivity in the German population

3 Study Design

3.1 Overview of Study Design and Dosing Regimen

This is a prospective, multi-center observational study in adult patients chronically infected with HCV receiving the interferon-free ABBVIE REGIMEN ± RBV.

University centers and outpatient clinics qualified by training and experience in the management of patients with CHC participate in this study.

The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study.

After written patient authorization has been obtained, patient data including demographic data, HCV disease characteristics, co-morbidities, co-medication, treatment details, and laboratory assessments as recorded in the patient's medical records (source documentation) are documented in the electronic case report form (eCRF). Patients are observed for the duration of the ABBVIE REGIMEN therapy and for up to 48 weeks after treatment completion.

The observational period for patients receiving 12 weeks of ABBVIE REGIMEN is max. 60 weeks (12 weeks treatment and 48 weeks post-treatment observation) and for patients receiving 24 weeks of ABBVIE REGIMEN the observational period is max. 72 weeks (24 weeks treatment and 48 weeks post-treatment observation).
Follow-up visits, treatment, procedures and diagnostic methods follow physicians’ routine clinical practice. The observational study period entails the following data collection schemes, data documented are those closest to the time windows as indicated in Figure 1:

- 12-week treatment regimen: five visits plus two interim data collection windows
- 24-week treatment regimen: five visits plus three interim data collection windows

This schedule is based on the anticipated regular follow-up for patients undergoing treatment for CHC.

**Figure 1 - Study Flowchart**

---

### 3.2 Sample Size Calculation

In studies investigating the interferon-free ABBVIE REGIMEN ± RBV, SVR12 rates of about 95% were observed, even in difficult-to-treat CHC patients (e.g. cirrhotic G1a treatment experienced patients). To describe in routine clinical practice the effectiveness of the ABBVIE REGIMEN ± RBV in patients with CHC a precise estimate of the SVR12 rates in the core population of this study should be achieved (see Section 4.2.1 for the definition of the core population).

It is expected, that during the planned recruitment period of 12 months about 650 patients with ABBVIE REGIMEN ± RBV can be included into this observational study, and that at least 620 patients will be evaluable in the core population. As obvious from Table 1, if the SVR12 rate is at least 95%, then with 620 patients the width of the 95% confidence interval (CI) will not be wider than 3.5%. Even in the case that fewer patients will be enrolled and only 590 patients can be evaluated in the core population, the 95% CI will have a width of ≤3.6% for a SVR12 rate of 95%.

**Table 1**  **Width of 95% Confidence Interval for SVR12**
4 Statistical Considerations and Analytical Plan

4.1 Primary and Secondary Parameters

4.1.1 Primary Effectiveness Parameter

The percentage of patients achieving SVR12 (HCV RNA <50 IU/mL 12 weeks [i.e. 70 to 126 days] after the last actual dose of the ABBVIE REGIMEN).

Please note, in the study protocol no upper boundary for the time window was specified. The upper boundary of 126 days was introduced to achieve consistency with other studies investigating the ABBVIE REGIMEN ± ribavirin (RBV) for the treatment of CHC. For the handling of missing values see section 4.2.3.

4.1.2 Secondary Parameters

The secondary effectiveness endpoints are:

- The percentage of patients with virological response (HCV RNA <50 IU/mL) at EoT (defined as last intake of ABBVIE REGIMEN or ribavirin)
- The percentage of patients with relapse (defined as HCV RNA <50 IU/mL at EoT followed by HCV RNA ≥50 IU/mL)
- The percentage of patients with breakthrough (defined as at least one documented HCV RNA <50 IU/mL followed by HCV RNA ≥50 IU/mL during treatment).
- Rapid virological response at week 4 (RVR 4, i.e. patients with HCV RNA < 50 IU/mL at week 4)
- Sustained virological response 24 weeks after EoT (SVR24, i.e. patients with HCV RNA < 50 IU/mL 24 weeks after EoT)
- Sustained virological response 48 weeks after EoT (SVR48, i.e. patients with HCV RNA < 50 IU/mL 48 weeks after EoT)
- The number and percentage of patients meeting each and any of the following SVR12 non-response categories:
  - On-treatment virologic failure (breakthrough [defined as above] or failure to suppress [each measured on-treatment HCV RNA value ≥50 IU/mL])
  - Relapse (defined as HCV RNA <50 IU/mL at EoT followed by HCV RNA ≥50 IU/mL post-treatment for subjects who complete treatment [not more than 7 days shortened])
  - Premature study drug discontinuation with no on-treatment virologic failure

### Table: SVR12 rates and 95% Confidence Interval

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>SVR12 rates</th>
<th>95% Confidence Interval*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Lower Limit</td>
</tr>
<tr>
<td>620</td>
<td>95%</td>
<td>93.0</td>
</tr>
<tr>
<td>590</td>
<td>95%</td>
<td>92.9</td>
</tr>
<tr>
<td>62</td>
<td>95%</td>
<td>86.5</td>
</tr>
</tbody>
</table>

* exact two-sided 95% confidence interval according to Wilson’s Score method

Assuming, that in total 620 patients will be evaluable, and subgroups of interest consist of at least 10% of the entire group (i.e. ≥62 patients), then the width of the 95% CI will be <12% for a SVR12 rate of 95%, which is also considered sufficiently precise for subgroup analyses.
o Missing SVR12 data and/or none of the above criteria

Further secondary variables are:

- Type of treatment regimen (± Dasabuvir, ± RBV, intended and actual combination, dose and duration)
- Adherence
  o Percentage of the DAA dose taken in relation to the target dose of DAA (cumulative dose taken divided by target dose in percent)
  o Percentage of the RBV dose taken in relation to the target dose of RBV (cumulative dose taken divided by target dose in percent)
  o Percentage of missed RBV treatment days in relation to the target number of RBV treatment days
- Co-morbidities and concomitant medication
- Serious and non-serious adverse events and pregnancy occurrences
- Questionnaires on PROs: e.g. PAM-13, FACIT-Fatigue, PRISM and work productivity and activity impairment (WPAI) questionnaire prior to treatment initiation, at EoT as well as 12, 24 and 48 weeks after EoT

No data will be imputed for any effectiveness or safety analyses except for the analyses of the HCV RNA endpoints and PRO questionnaires (if applicable). For further details see sections 4.2.3 and 4.2.7.2.3, respectively.

4.2 Statistical and Analytical Methods

4.2.1 Analysis Populations and Analysis Groups

Population of Patients Enrolled [EP]

The population of patients enrolled comprises all patients who voluntarily sign and date a patient authorization to use and/or disclose his/her anonymized health data prior to inclusion into the study and data were captured in the eCRF.

Target Population [TP]

Patients will be included if the following applies:

- Age at least 18 years
- Confirmed CHC with genotype 1 and/or 4 only, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± RBV. The prescribed ABBVIE REGIMEN needs to be known.
- Have voluntarily signed and dated a patient authorization to use and/or disclose his/her anonymized health data prior to inclusion into the study
- Must not be participating or intending to participate in a concurrent interventional therapeutic trial
Core Population [CP]
The core population is defined as all patients of the target population (TP) (definition see above), who are adequately treated according to the standard of care and within local label recommendations for their specific disease characteristics (cirrhotic status, genotype). The following patients will be excluded from the CP:

- Patients with unknown fibrosis status
- Cirrhotic patients with genotype 1α not receiving ribavirin
- Patients with genotype 1 for whom 2DAA instead of 3DAA is prescribed
- Patients with genotype 4 not receiving RBV

Non-Core Population [NCP]
 Patients in the TP who are not in the CP.

Core Population with Sufficient Follow-up [CPSFU {12, 24, 48}]
In addition, the core population with sufficient follow-up data regarding SVR12, SVR24 or SVR48, respectively, is defined as all CP patients,

- who have evaluable HCV RNA data ≥70 days, >126 days or >210 days, respectively, after the last actual dose of the ABBVIE REGIMEN
- or a HCV RNA value ≥50 IU/mL at the last measurement post-baseline
- or had HCV RNA <50 IU/mL at the last measurement post-baseline, but no HCV RNA measurement ≥70 days, >126 days or >210 days, respectively, after the last actual dose of the ABBVIE REGIMEN due to reasons related to safety (e.g. dropped out due to adverse event) or virologic failure (e.g. virologic failure such as relapse is reported in the electronic case report form (eCRF) but date and value of the corresponding HCV RNA test is missing).

This means only (1) patients who had virological response at their last on-treatment or post-treatment measurement, but had no post-treatment HCV RNA measurements ≥70 days, >126 days or >210 days, respectively, for reasons not related to safety or effectiveness (e.g. lost-to-follow-up or patient not willing to perform an additional HCV RNA test ≥70 days, >126 days or >210 days post-treatment, respectively) and (2) patients who had no post-baseline HCV RNA measurements for reasons not related to safety or effectiveness, and (3) patients with missing end of treatment date for reasons not related to safety or effectiveness, will be excluded from this analysis.

Safety population [SP]
The safety population is defined as all enrolled patients who received at least one dose of the ABBVIE REGIMEN. The prescribed ABBVIE REGIMEN needs to be known.
EP and TP analysis groups

The EP/TP analysis groups are defined according to the patient's fibrosis status and genotype/subtype and standard summaries are structured as follows:

- **Total (regardless of cirrhosis status)**
  1. Total (regardless of genotype)
  2. G1 (Total)
  3. G1a (including mixed G1 subtypes and patients with G1 unknown subtype)
  4. G1b
  5. G4 (non-G1)
  6. Other/unknown genotype (only for EP)

- **Patients with cirrhosis**
  7. Total (regardless of genotype)
  8. G1 (Total)
  9. G1a (including mixed G1 subtypes and patients with unknown G1 subtype)
  10. G1b
  11. G4 (non-G1)
  12. Other/unknown genotype (only for EP)

- **Patients without cirrhosis**
  13. Total (regardless of genotype)
  14. G1 (Total)
  15. G1a (including mixed G1 subtypes and patients with unknown G1 subtype)
  16. G1b
  17. G4 (non-G1)
  18. Other/unknown genotype (only for EP)

- **Patients with unknown fibrosis status**
  19. Total (regardless of genotype)
  20. G1 (Total)
  21. G1a (including mixed subtypes and patients with unknown subtype)
  22. G1b
  23. G4 (non-G1)
  24. Other/unknown genotype (only for EP)

(HCV genotypes will be combined as follows: G1 [total], G1a*, G1b, G4 [non-G1]. * includes mixed or other G1 subtypes and patients with unknown G1 subtypes.)
Most recent stage of liver fibrosis will be categorized as follows: No cirrhosis/Transition to cirrhosis, Cirrhosis. Only one method should be selected by the physicians to report stage of fibrosis.

Nevertheless, if there are multiple answers the following priority will be used:

1. Biopsy,
2. Non-invasive,

For biopsy as assessment method the respective categories are defined as follows:

- “No cirrhosis” is defined by “No fibrosis”, “Mild/minimal fibrosis”, “Moderate fibrosis”
- “Transition to cirrhosis” is defined by “Advanced Fibrosis”
- “Cirrhosis” is defined by “Cirrhosis”).

**CP analysis groups and related treatment regimens**

The CP analysis groups are defined according to the patient’s fibrosis status and genotype/subtype. The standard summaries by CP analysis groups in the CP and CPSFU population are structured follows (is not specified otherwise):

- Total (regardless of cirrhosis status)
  1. Total (regardless of genotype)
  2. G1 (Total)
  3. G1a (including mixed subtypes and patients with unknown subtype)
  4. G1b
  5. G4 (non-G1)

- Patients with cirrhosis
  6. Total (regardless of genotype)
  7. G1 (Total)
  8. G1a (including mixed subtypes and patients with unknown subtype)
  9. G1b
  10. G4 (non-G1)

- Patients without cirrhosis
  11. Total (regardless of genotype)
  12. G1 (Total)
  13. G1a (including mixed subtypes and patients with unknown subtype)
  14. G1b
  15. G4 (non-G1)
### SP analysis groups

The SP analysis groups are defined according to the treatment regimen and patient’s fibrosis status. The standard summaries by SP groups in the safety population are as follows (if not specified otherwise):

- **Total (regardless of cirrhosis status)**
  - (1) Total
  - (2) 2DAA w/o RBV
  - (3) 2DAA + RBV
  - (4) 3DAA w/o RBV
  - (5) 3DAA + RBV

- **Patients with cirrhosis**
  - (6) Total
  - (7) 2DAA w/o RBV
  - (8) 2DAA + RBV
  - (9) 3DAA w/o RBV
  - (10) 3DAA + RBV

- **Patients without cirrhosis**
  - (11) Total
  - (12) 2DAA w/o RBV
  - (13) 2DAA + RBV
  - (14) 3DAA w/o RBV
  - (15) 3DAA + RBV

- **Patients with unknown fibrosis status**
  - (16) Total
  - (17) 2DAA w/o RBV
  - (18) 2DAA + RBV
  - (19) 3DAA w/o RBV
  - (20) 3DAA + RBV

(2DAA - paritaprevir/r-ombitasvir, 3 DAA - paritaprevir/r-ombitasvir + dasabuvir, RBV – ribavirin taken, w/o RBV – no ribavirin taken)
NCP analysis groups
The summary tables for the NCP will only show the data pooled for all patients in the NCP without any subgrouping by genotype and/or fibrosis status.

4.2.2 Definition of Baseline and Visit Time Windows
This observational study covers three documentation periods, see Figure 1. An overview of data to be collected throughout the study is summarized in Table 3.
### Table 2 - Data Documentation Schedule

<table>
<thead>
<tr>
<th>Assessment/Procedure</th>
<th>Baseline</th>
<th>Treatment Period</th>
<th>Post-treatment (PT) Period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>On-treatment visits</td>
<td>Mid treatment visit</td>
</tr>
<tr>
<td>Patient authorization</td>
<td>X&lt;sup&gt;a&lt;/sup&gt;</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Demographic information</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL28B</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relevant CHC disease characteristics</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver fibrosis stage</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHC treatment history</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCV genotype and subtype</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCV RNA samples</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Clinical chemistry and hematology</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>ABBVIE REGIMEN initiation documentation</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABBVIE REGIMEN adherence</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Concomitant medication</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Relevant medical history, co-morbidities</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sAE, AE and pregnancy reporting</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>For patients receiving RBV: Evidence, in accordance with local label, that female patient or female partner of male patient is not pregnant</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient questionnaires – FACIT-F</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Patient questionnaires – WPAI</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient questionnaires – PRISM</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient questionnaires – PAM-13</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: EoT = End of Treatment (at Week 12 or 24 or at premature discontinuation), PT = Post-Treatment

- **a** Written patient authorization must be obtained before any data documentation in the eCRF
- **b** Patients who prematurely discontinue should return to the site to document EoT data
- **c** Tolerability documentation until PT week 4
- **d** Pregnancy reporting for patients treated with DAA plus RBV

In accordance with the non-interventional nature of the study all HCV RNA measurements will be performed at the sole discretion of the physician and all HCV RNA measurements have to be entered into the eCRF. All recorded HCV RNA values will be assigned to appropriate time points (baseline, on-treatment visits, EoT visit, post-treatment visits) as follows:
<table>
<thead>
<tr>
<th>Phase</th>
<th>Time point</th>
<th>Time Window</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Treatment</td>
<td>Baseline</td>
<td>Last value prior to start of study treatment (i.e. ≤ study day 1)</td>
</tr>
<tr>
<td>On-treatment</td>
<td>Study day</td>
<td>Study day during treatment period^# (Study day 1 = first treatment day)</td>
</tr>
<tr>
<td></td>
<td>Treatment</td>
<td>15 - 42^</td>
</tr>
<tr>
<td></td>
<td>Week 4 (RVR*)</td>
<td></td>
</tr>
<tr>
<td>EoT</td>
<td>Actual EoT</td>
<td>Study day of last dose# (28 days prior to last dose - 7 days post last dose)</td>
</tr>
<tr>
<td>Post Treatment</td>
<td>12 weeks (SVR 12 window)</td>
<td>&gt;= 70-126 days post last dose</td>
</tr>
<tr>
<td></td>
<td>24 weeks (SVR 24 window)</td>
<td>127-210 days post last dose</td>
</tr>
<tr>
<td></td>
<td>48 weeks (SVR 48 window)</td>
<td>&gt; 210 days post last dose</td>
</tr>
</tbody>
</table>

^values must also be <= 7 days post last dose

# >= study day 2

*RVR = rapid virological response
All reported safety laboratory test results will be assigned to one of the time points using the time windows specified in the table below.

**Table 4 - Analysis Time Windows for Safety Laboratory Data**

<table>
<thead>
<tr>
<th>Phase</th>
<th>Time point</th>
<th>Time Window</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Treatment</td>
<td>Baseline</td>
<td>Last value prior to start of study treatment (i.e. ≤ study day 1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Study day during treatment period (Study day 1 = first treatment day)</td>
</tr>
<tr>
<td>Treatment Weeks</td>
<td>4 (day 29)</td>
<td>15 – 42^</td>
</tr>
<tr>
<td></td>
<td>8 (day 57)</td>
<td>43 – 70^</td>
</tr>
<tr>
<td></td>
<td>12 (day 85)</td>
<td>71 – 98^</td>
</tr>
<tr>
<td></td>
<td>16 (day 113)</td>
<td>99 – 126^</td>
</tr>
<tr>
<td>EoT</td>
<td>Actual EoT</td>
<td>Study day of last dose# (28 days prior to last dose - 7 days post last dose)</td>
</tr>
<tr>
<td>Post Treatment</td>
<td>4 weeks</td>
<td>8– 56 post last dose</td>
</tr>
<tr>
<td></td>
<td>(28 days post last dose)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12 weeks</td>
<td>57 – 126 days post last dose</td>
</tr>
<tr>
<td></td>
<td>(84 days post last dose)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>24 weeks</td>
<td>127 – 252 days post last dose</td>
</tr>
<tr>
<td></td>
<td>(168 days post last dose)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>48 weeks</td>
<td>253 – 420 days post last dose</td>
</tr>
<tr>
<td></td>
<td>(336 days post last dose)</td>
<td></td>
</tr>
</tbody>
</table>

^values must also be <= 7 days post last dose

# >= study day 2

### 4.2.3 Handling of missing data

No data will be imputed for any effectiveness or safety analyses except for the analyses of the HCV RNA endpoints and certain PRO endpoints. The discussion of missing data imputation for the PRO endpoints is included in section 4.2.7.2.3.

HCV RNA values will be selected for an RVR, EOTR and SVR analysis based on visit windows as defined in Table 4. When there is no HCV RNA value in a visit window based on defined visit windows, the closest values before and after the window, regardless of the value chosen for the subsequent and preceding window, will be used for the flanking imputation described below. For analysis of RVR, EOT and SVR, if a subject has a missing HCV RNA value at a post-Day 1 visit but with undetectable or unquantifiable (LLoD or LLoQ ≤50 IU/mL) HCV RNA levels at both the preceding value and succeeding value, the HCV RNA level will be considered undetectable or unquantifiable, respectively, at this visit for this subject. In addition, if a subject has an
unquantifiable HCV RNA level at the preceding value and an undetectable HCV RNA level at the succeeding value, or vice versa, the HCV RNA level will be imputed as unquantifiable at this visit for this subject.

For analyses of RVR, subjects still missing a value for the visit after flanking imputation will be considered as a failure. For EoTR and SVR analysis, if there is no value in the appropriate window after flanking imputation but there is an HCV RNA value after the window, then it will be imputed into the EoTR or SVR window respectively. Subsequent to this flanking and backward imputation, if the HCV RNA value remains missing at a specific time point, then the subject will be considered as virological failure at this time point (i.e., not undetectable or unquantifiable).

If a subject starts another treatment for HCV, then all HCV RNA values for this subject measured on or after the start date of the new HCV treatment will be excluded from analyses. The subject will be considered a failure for summaries of viral response at all time points after the start of the new HCV treatment.

Due to the non-interventional nature of this study several different methods for determination of the HCV RNA value can be applied. For the purpose of the statistical analysis, a HCV RNA measurement is considered <50 IU/mL,

• if a PCR test was used

• and the test result is undetectable and the LLoD of the test is ≤50 IU/mL or the test result is unquantifiable (i.e. detected but below LLoQ) and the LLoQ is ≤50 IU/mL.

4.2.4 Site and Researcher Information

Data of the study sites and of the Researcher will be presented in summary tables.

The summary tables for site information will show absolute and relative frequencies for the institution type (private practice/ private hospital, general hospital, academic/ university hospital, other), the type of unit (general population, transplant, drug user, HIV/ HCV co-infection, hepatocellular carcinoma [HCC]), and the site location (urban, rural). Regarding type of unit multiple answers per site are possible.

The principle researcher experience will be summarized by presenting for each therapeutic specialty (hepatology, infectious disease, gastroenterology, internal medicine, transplant, general practitioner) the number and percentage of principle researchers, who have the specific experience. Furthermore, the number and percentage of sites with at least one researcher (i.e. including co-researcher) of the therapeutic specialty concerned and the number of HCV-infected patients typically seen per month at the site (<25, 25-50, 51-75, 76-100, >100), including the patients seen by co-researcher, will be summarized. Note: Multiple therapeutic specialties could be reported per researcher.

An overview of Tables for site and researcher information is given in Table 6.
Table 5  Overview of Outputs for Site and Researcher Information

<table>
<thead>
<tr>
<th>Output Title</th>
<th>Output Name</th>
<th>Analysis Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site Information - &lt;country&gt;</td>
<td>tsi_&lt;c&gt;</td>
<td>Sites with patients</td>
</tr>
<tr>
<td>Researcher Experience- &lt;country&gt;</td>
<td>tre_&lt;c&gt;</td>
<td>Sites with patients</td>
</tr>
</tbody>
</table>

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.5 Patient Disposition

The frequencies of patients belonging to the different populations (i.e. EP, TP, CP, CPSFU; SP) will be summarized by genotype and cirrhosis status and overall using the EP analysis groups as specified in section 4.2.1. The reasons for exclusion from a particular population will be also summarized in the frequency tables. Additionally, information on patient disposition will be listed.

Furthermore the frequency of patients not completing the study as defined per protocol (i.e. no HCV RNA assessment performed at least 10 weeks post-treatment), will be summarized by treatment regimen and cirrhosis status and additionally by genotype and cirrhosis status and overall for the SP and CP. The reasons for not completing the study as entered on the CRF will be displayed (i.e. failure to return, insufficient virological response (HCV RNA detectable at end of treatment, relapse post-treatment), patient never started treatment, withdrawn consent, death, other).

Additionally, the main reason for early termination of the ABBVIE regimen (AE or SAE [Physician decision], virological non-response [Physician decision], rebound or breakthrough [Physician decision], resistance to DAA [Physician decision], patient refused to continue treatment, patient withdrew consent to participate in the study, lost to follow-up, other, unknown [if actual duration is shortened for more than 7 days]) and Ribavirin (Anemia, Nausea/Vomiting, Rash, Other) will be summarized by treatment regimen and cirrhosis status and additionally by genotype and cirrhosis status and overall for the following different analysis populations: CP and SP.

Finally the study regimens assigned at baseline will be summarized (a) by genotype and cirrhosis status and (b) by genotype and pre-treatment status (treatment naïve vs treatment experienced) for CP and SP.

An overview of tables is given in Table 7.
Table 6  Overview of Outputs for Patient Disposition

<table>
<thead>
<tr>
<th>Output Title</th>
<th>Output Short Name</th>
<th>Analysis Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Disposition by Genotype and Cirrhosis Status – EP - &lt;country&gt;</td>
<td>tdis_&lt;c&gt;_gc_ep</td>
<td>Patients Enrolled</td>
</tr>
<tr>
<td>Listing of Patient Disposition - EP- &lt;country&gt;</td>
<td>tdis_&lt;c&gt;_ep</td>
<td>Patients Enrolled</td>
</tr>
<tr>
<td>Premature Termination of the Study and its Main Reason by &lt;Treatment Regimen/ Genotype&gt; and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>tps_&lt;c&gt;_tg_c_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Premature Termination of the Study and its Main Reason by &lt;Treatment Regimen/ Genotype&gt; and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tps_&lt;c&gt;_tg_c_sp</td>
<td>Safety population</td>
</tr>
<tr>
<td>Premature Termination of Treatment and its Main Reason by &lt;Treatment Regimen/ Genotype&gt; and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>tpt_&lt;c&gt;_tg_c_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Premature Termination of Treatment and its Main Reason by &lt;Treatment Regimen/ Genotype&gt; and Cirrhosis Status - SP- &lt;country&gt;</td>
<td>tpt_&lt;c&gt;_tg_c_sp</td>
<td>Safety population</td>
</tr>
<tr>
<td>Treatment Regimen by Genotype and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>trr_&lt;c&gt;_gc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Treatment Regimen by Genotype and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>trr_&lt;c&gt;_gc_sp</td>
<td>Safety population</td>
</tr>
<tr>
<td>Treatment Regimen by Genotype and Pretreatment Status - CP - &lt;country&gt;</td>
<td>trr_&lt;c&gt;_gpe_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Treatment Regimen by Genotype and Pretreatment Status - SP - &lt;country&gt;</td>
<td>trr_&lt;c&gt;_gpe_sp</td>
<td>Safety population</td>
</tr>
</tbody>
</table>

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.6  Baseline Characteristics

All baseline and disease characteristics will be summarized for the CP stratified by genotype and cirrhosis status and overall, in accordance with the CP analysis groups specified in section 4.2.1). Corresponding baseline summaries will be repeated for the TP. In addition, these characteristics will be summarized by cirrhosis status and treatment regimen and overall for the SP, in accordance with the SP analysis groups specified in section 4.2.1. Summary statistics (n, mean, median, standard deviation [SD], minimum, maximum) will be generated for continuous variables (e.g. age and body mass index [BMI]). The number and percentage of patients will be presented for categorical variables (e.g. gender and race).

An overview of tables for baseline characteristics is given in Table 8.

4.2.6.1  Socio-demographic characteristics

Demographic data will be summarized in a table displaying:

- Age (continuous and grouped by 18-65, 66-84, >=85 years)
Gender (Male, Female)
Race/Ethnic Origin (White/Caucasian, Black, Asian/Oriental, Native American/American Indian, Other)
Interleukin 28B (IL28B) genotype, rs12979860 (CC, CT, TT, Unknown)
Interleukin 28B (IL28B) genotype, rs8099917 (TT, TG, GG, Unknown)
Height [cm]
Weight [kg]
BMI [kg/m²]

4.2.6.2 CHC disease characteristics

CHC disease characteristics will be summarized in a table displaying:

Years since diagnosis of HCV infection
Mode of HCV infection (Drug use (i.v.), Drug use (non i.v.), Sexual transmission, Occupational [HCV acquired while doing his/her job, e.g. physicians or nurses], Blood transfusion or transplantation, Perinatal, Contaminated medical device [other than i.v. drug use], Other, Unknown)
Pretreatment Status (Naïve, Experienced)
HCV Genotype and Subtype (as recorded in the CRF)
Most recent stage of liver fibrosis (No cirrhosis, Transition to cirrhosis, Cirrhosis) [Only one method should be selected by the physicians to report stage of fibrosis. Nevertheless, if there are multiple answers the following priority will be used:
1. Biopsy,
2. Non-invasive,
For biopsy as assessment method the respective categories are defined as follows:
- “No cirrhosis” is defined by “No fibrosis”, “Mild/minimal fibrosis”, “Moderate fibrosis”
- “Transition to cirrhosis” is defined by “Advanced Fibrosis”
- “Cirrhosis” is defined by “Cirrhosis”.
Assessment method for liver fibrosis staging (Biopsy, Non-invasive, Clinical/Best guess) [If multiple answers are ticked, the priority is as follows: biopsy, non-invasive, clinical/best guess.]
Time between treatment start and biopsy assessment [months] (continuous)
Time since biopsy [months] (categorized as ≤3, >3-6, >6-12, >12-24, >24-60, >60 months)
Metavir fibrosis score (0, 1, 2, 3, 4)
Ishak fibrosis score (0, 1, 2, 3, 4, 5, 6)
Batts/Ludwig fibrosis score (0, 1, 2, 3, 4)
Knodell fibrosis score (0, 1, 3, 4)
Scheuer fibrosis score (0, 1, 2, 3, 4)
Time between treatment start and FibroScan assessment [months] (continuous)
Time since FibroScan [months] (categorized as ≤1, >1-2, >2-6, >6-12, >12-24, >24 months)
FibroScan [kPa] (<8.8, 8.8-<9.6, 9.6-<14.6, ≥14.6)
Time between treatment start and ARFI assessment [months] (continuous)
Time since ARFI [months] (categorized as ≤1, >1-2, >2-6, >6-12, >12-24, >24 months)
- AFRI [m/s]
- Time between treatment start and FibroTest assessment [months] (continuous)
- Time since FibroTest [months] (categorized as ≤1, >1-2, >2-6, >6-12, >12-24, >24 months)
- Results of FibroTest (<=0.21, 0.22-0.27, 0.28-0.31, 0.32-0.48, 0.49-0.58, 0.59-0.72, 0.73-0.74, >=0.75)
- Esophageal varices (Yes, No, Unknown)
- History of liver decompensation (No - never decompensated, Yes - but currently compensated, Yes – still decompensated [including patients with a Child Pugh Score >=7], Current signs/symptoms – Total, Current signs/symptoms – Coagulopathy, Current signs/symptoms – Hyperbilirubinemia, Current signs/symptoms – Hepatic encephalopathy, Current signs/symptoms – Hypo-albuminemia, Current signs/symptoms – Ascites, Current signs/symptoms – Bleeding from esophageal varices [multiple answers are possible])
- Child Pugh Score (categorized as 5-6, 7-9, 10-15)

### 4.2.6.3 CHC treatment history

For treatment-experienced patients the most recent prior treatment and the outcome to prior treatment as reported by the investigator in the eCRF (Null response, Partial response, Breakthrough, Relapse, Sustained virological response (SVR) followed by reinfection, Discontinued [and none of the above], Unknown / None of the above) will be summarized in frequency tables. In addition to the frequency of each medication (IFN alpha, PEG IFN-alpha, IFN NOS, PEG IFN NOS, Ribavirin, DAA), the frequency of the combinations (pegIFN alpha + RBV, IFN alpha + RBV, XXX) will be summarized.

### 4.2.6.4 Co-morbidities and co-infections

A summary table will present the absolute and relative frequencies of HCV co-infections, CHC related comorbidities and other co-morbidities, in more detail:

- HCV Co-infections
  - Human immunodeficiency virus (HIV)
  - Hepatitis B virus (HBV)
  - Tuberculosis
  - Schistosomiasis
- Liver and/ or CHC related co-morbidities
  - Liver transplantation
  - Hepatocellular carcinoma
  - Steatosis (non-alcoholic)
  - Alcoholic liver disease
  - Primary biliary cirrhosis
  - Auto-immune hepatitis
• Other co-morbidities
  o Kidney transplant
  o Chronic kidney disease (Mild, Moderate, Severe, Currently on dialysis, Currently not on dialysis)
  o Psychiatric disorders (Depression, Bipolar disorder, Schizophrenia, Personality disorder)
  o Diabetes mellitus (Type 1, Type 2)
  o Insulin resistance
  o Metabolic syndrome
  o Lipid disorder
  o Hyperthyroidism
  o Hypothyroidism
  o Cardiovascular disease (Myocardial infarction, Angina pectoris, Hypertension, Stroke)
  o Immunologically mediated disease
  o Hemophilia
  o Thalassemia
  o Sickle cell anemia
  o V. Willebrand disease
  o Psychoactive substance dependency (Active injection drug use, Inhalate cocaine, Marihuana/ cannabis, Opiate substitution)
  o Other

The patient’s alcohol consumption will be displayed in a further table, i.e.:

• Alcohol use (None, Yes – occasional, Yes – regular, Ex-drinker [6 units/drinks per day, none in the last 3 months])
• Average number of units/drinks per week (if regular alcohol use is reported)

One unit/drink is defined as 10 milliliters (or approximately 8 grams) of pure alcohol and equals: 200 ml of beer or 100 ml of wine or 20 ml of hard liquor.

4.2.6.5 CHC related and other laboratory data at baseline

The laboratory data at baseline are the most recent available data prior to first administration of the ABBVIE REGIMEN (including day 1, see Table 5). All reported clinical laboratory test results will be assigned to one of the time points using the time windows specified in the Table 5.
A summary table will show CHC related laboratory data at baseline, i.e. HCV RNA in IU/mL, HCV RNA in log10 IU/mL, and HCV RNA categorized using 400,000, 800,000, 6,000,000 and 10,000,000 as cut-offs, ALT, ALT ratio, AST, AST ratio, APRI, FIB-4. ALT-ratio, AST ratio, APRI and FIB-4 will be calculated as follows:

ALT ratio = ALT value / upper limit of normal (ULN) of local laboratory

AST ratio = AST value / ULN of local laboratory

APRI = 100 x AST [IU/L] / (ULN of AST [IU/L] x Platelets [10**9/L]) (APRI= aspartate aminotransferase to platelet ratio index [1]; calculated, if laboratory assessments took place within 30 days)

FIB-4 = (Age [years] x AST [IU/L]) / (Platelets [10**9/L] x Square root of ALT [IU/L]) (FIB-4= Fibrosis 4 index [2]; calculated, if laboratory assessments took place within 30 days)

In addition the following other key laboratory data at baseline will be summarized:
- GT, total bilirubin, albumin, creatinine, creatinine clearance (continuous and categorize as Grade 1 [60-<LLN mL/min], Grade 2 [30-<60 mL/min], Grade 3 [15-<30 mL/min], Grade 4 [<15 mL/min]; if LLN is missing 75 mL/min is used), AFP, hemoglobin, platelets, prothrombin time, and INR (if documented instead of prothrombin time). The creatinine clearance will be calculated as follows:

Creatinine clearance [ml/min] = (140-age) x Weight (in kg) x constant/Creatinine (in μmol/L) (constant is 1.23 for men and 1.04 for women; calculated by Cockcroft-Gault-Formula)

A further table CD4 and HIV-RNA test results are displayed for patients with HIV only.
### Table 7  Overview of Outputs for Baseline Characteristics

<table>
<thead>
<tr>
<th>Output Title</th>
<th>Output Short Name</th>
<th>Analysis Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Socio-demographic Characteristics by Genotype and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>tdm_&lt;c&gt;_gc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Socio-demographic Characteristics by Genotype and Cirrhosis Status - TP - &lt;country&gt;</td>
<td>tdm_&lt;c&gt;_gc_tp</td>
<td>Target population</td>
</tr>
<tr>
<td>Socio-demographic Characteristics by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tdm_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
</tr>
<tr>
<td>CHC Disease Characteristics by Genotype and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>tdc_&lt;c&gt;_gc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>CHC Disease Characteristics by Genotype and Cirrhosis Status - TP - &lt;country&gt;</td>
<td>tdc_&lt;c&gt;_gc_tp</td>
<td>Target population</td>
</tr>
<tr>
<td>CHC Disease Characteristics by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tdc_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
</tr>
<tr>
<td>CHC Related Laboratory Variables at Baseline by Genotype and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>tlcdb_&lt;c&gt;_gc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>CHC Related Laboratory Variables at Baseline by Genotype and Cirrhosis Status - TP - &lt;country&gt;</td>
<td>tlcdb_&lt;c&gt;_gc_tp</td>
<td>Target population</td>
</tr>
<tr>
<td>CHC Related Laboratory Variables at Baseline by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tlcdb_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
</tr>
<tr>
<td>Other Key Laboratory Variables at Baseline by Genotype and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>tkldb_&lt;c&gt;_gc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Other Key Laboratory Variables at Baseline by Genotype and Cirrhosis Status - TP - &lt;country&gt;</td>
<td>tkldb_&lt;c&gt;_gc_tp</td>
<td>Target population</td>
</tr>
<tr>
<td>Other Key Laboratory Variables at Baseline by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tkldb_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
</tr>
<tr>
<td>CHC Treatment History in Treatment Experienced Patients by Genotype and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>th_&lt;c&gt;_gc_cp_ep</td>
<td>Core population: treatment-experienced patients</td>
</tr>
<tr>
<td>CHC Treatment History in Treatment Experienced Patients by Genotype and Cirrhosis Status - TP - &lt;country&gt;</td>
<td>th_&lt;c&gt;_gc_tp_ep</td>
<td>Target population: treatment-experienced patients</td>
</tr>
<tr>
<td>CHC Treatment History in Treatment Experienced Patients by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>th_&lt;c&gt;_tc_sp_ep</td>
<td>Safety population: treatment-experienced patients</td>
</tr>
<tr>
<td>Co-morbidities and Co-infections by Genotype and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>tcoi_&lt;c&gt;_gc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Co-morbidities and Co-infections by Genotype and Cirrhosis Status - TP - &lt;country&gt;</td>
<td>tcoi_&lt;c&gt;_gc_tp</td>
<td>Target population</td>
</tr>
<tr>
<td>Co-morbidities and Co-infections by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tcoi_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
</tr>
</tbody>
</table>
Alcohol Consumption by Genotype and Cirrhosis Status - CP - <country>  tac_<c>_gc_cp  Core population

Alcohol Consumption by Genotype and Cirrhosis Status - TP - <country>  tac_<c>_gc_tp  Target population

Alcohol Consumption by Treatment Regimen and Cirrhosis Status - SP - <country>  tac_<c>_tc_sp  Safety population

CD4 and HIV RNA in Patients with HIV at Baseline by Genotype and Cirrhosis Status - CP - <country>  tlchb_<c>_gc_cp_hiv  Core population: patients with HIV

CD4 and HIV RNA in Patients with HIV at Baseline by Genotype and Cirrhosis Status - TP - <country>  tlchb_<c>_gc_tp_hiv  Target population: patients with HIV

CD4 and HIV RNA in Patients with HIV at Baseline by Treatment Regimen and Cirrhosis Status - SP - <country>  tlchb_<c>_tc_sp_hiv  Safety population: patients with HIV

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.7 Analyses of the Objectives

4.2.7.1 Primary Effectiveness Variable

The primary objective of this study is to estimate the SVR12 rates in HCV patients treated according to the ABBVIE regimen.

Therefore the simple percentage of patients achieving SVR12 (for definition see section 4.1.1) will be calculated and a two-sided 95% confidence interval (CI) of the percentage will be computed based on the Wilson’s Score method.

The primary effectiveness analysis on clinical outcomes will be performed on all patients in the CP stratified by genotype and cirrhosis status and overall.

In the framework of sensitivity analyses the primary analyses will be repeated for the CPSFU. Furthermore, the SVR12 rates will be also determined for all patients of the NCP.

An overview of Tables is given in Table 9.

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.7.2 Secondary Variables

4.2.7.2.1 Secondary Effectiveness Variables

Response

For the other response rates (i.e. RVR, SVR24, SVR48, EoT response rate, relapse rate, viral breakthrough), the simple percentage of patients and a two-sided 95% confidence interval (CI) of the percentage will be computed (based on the Wilson’s score method) as well. The RVR and EoT response rates will be reported for CP and the SVR24 and SVR48 rates will be reported for the respective CPSFU, stratified by genotype and cirrhosis status and overall. The relapse rates will be estimated stratified by SVR window (i.e. during SVR12 window=relapse12, during SVR24
window=relapse\textsubscript{24}, after SVR24 window=relapse\textsubscript{late}) and stratified by genotype and cirrhosis status and overall in patients of the CP with EoT response who fulfilled the following criteria:

- completed treatment as defined previously,
- had at least one HCV RNA measurement $\geq$ 70 days post-treatment or was a treatment failure between EoT and 70 days post-treatment.

Viral breakthrough rates [defined as at least one documented HCV RNA $<$50 IU/mL followed by HCV RNA $\geq$50 IU/mL during treatment] will be estimated overall and stratified by genotype and cirrhosis status in all patients of the CP, who have at least one undetectable or unquantifiable, on-treatment HCV RNA measurement and at least one on-treatment or EoT measurement thereafter.

**Non-Response**

In another table, the numbers and the percentages of the SVR12 non-responder categories and responder will be summarized for CP patients, overall and stratified by genotype and cirrhosis status. The following SVR12 non-response categories will be considered:

- On-treatment virologic failure (breakthrough [defined as at least one documented HCV RNA $<$50 IU/mL followed by HCV RNA $\geq$50 IU/mL during treatment] or failure to suppress [each measured on-treatment HCV RNA value $\geq$50 IU/mL])
- Relapse (defined as HCV RNA $<$50 IU/mL at EoT followed by HCV RNA $\geq$50 IU/mL post-treatment and completed treatment as defined previously)
- Death and none of the above
- Premature study drug discontinuation with no on-treatment virologic failure and none of the above
- Insufficient virological response, other than those mentioned above (patients for whom insufficient virological response was reported, or who had HCV RNA $\geq$50 IU/mL post EoT) and none of the above
- Missing SVR12 data and/or none of the above criteria

Virological response rates and non-response categories will be displayed for patients who completed treatment with ABBVIE regimen, as well.

**SVR12 (Exploratory Analyses)**

Univariate and multiple logistic regression (MLR) methods will be used to investigate the impact of various explanatory covariates (patient and disease characteristics) at baseline on SVR12.

These analyses will be of exploratory nature, data driven, and will be performed for CP population. Univariate logistic regression will be performed first and then backward selection procedures will be applied to generate the final MLR model. A $p$-value $<0.05$ will be used for the covariates to stay in the model in a backward elimination step. If the percentage of patients with available data for a variable is lower than 80% of the patient group analyzed, then this variable will not be considered in the MLR analysis.

The variables to be considered are as follows:
• Key demographic information
  o Age (continuous)
  o Gender (Female [reference], Male)
  o Race/ethnic origin (White/Caucasian [reference], Black, Asian/Oriental, Other [all other races]); at least two categories with at least 10% of the patients each have to exist, so that this variable will be considered
  o Weight (continuous)
  o BMI (continuous)
  o IL28B, rs12979860 (CC [reference], CT or TT); patients with unknown genotype are excluded from the respective analyses.

• CHC disease characteristics
  o Years since diagnosis (continuous)
  o Mode of CHC infection (Drug use [reference], Other [all other answers excluding unknown], unknown);
  o Most recent stage of liver fibrosis (No cirrhosis/Transition to cirrhosis [reference], Cirrhosis; for definition see 4.2.6.2);

• HCV RNA level at baseline (log_{10} IU/mL)

• HCV genotype (G1a*, G1b, G4; for definition see section 4.2.6.2)

• Type of treating institute (Private Practice / Private Hospital, Academic / University Hospital, General Hospital, Other)

• Co-infections (every patient not reporting the respective co-infection is considered as not having the respective co-infection)
  o HIV (No [reference], Yes)
  o HBV (No [reference], Yes)

• Liver and/or CHC related co-morbidities (every patient not reporting the respective co-morbidity is considered as not having the respective co-morbidity)
  o Liver transplantation (No [reference], Yes)
  o Steatosis (non-alcoholic) (No [reference], Yes)
  o Decompensated liver disease (No [reference], Yes)

• Other co-morbidities (every patient not reporting the respective co-morbidity is considered as not having the respective co-morbidity)
  o Depression (No [reference], Yes)
  o Diabetes mellitus (No [reference], Type 1/Type 2)
Hypertension (No [reference], Yes)
Immunologically mediated disease (No [reference], Yes)
Hypothyroidism (No [reference], Yes)

Alcohol use (None [reference], Yes –occasional, Yes –regular, Exdrinker)

Key clinical chemistry and hematology laboratory variables at baseline
- ALT ratio (continuous, see 4.2.6.5)
- AST ratio (continuous, see 4.2.6.5)
- Platelets \(10^9/L\) (continuous)

Prior treatment status (HCV treatment naïve [reference], HCV treatment experienced)

Additionally, an interaction term for cirrhosis status and genotype will be considered. If the most recent stage of liver fibrosis status (No cirrhosis/Transition to cirrhosis vs Cirrhosis), the genotype (G4, G1b vs G1a) or the interaction of both remains in the final model, then additional MLR might be considered for the subgroups concerned, taking into account the treatment regimen (e.g. in cirrhotic G1 patients: RBV vs no RBV and 12 wks vs 24 weeks).

The categories pre-specified above could be modified in the analyses if this is supported by the data (e.g. categories could be combined, if their impact on SVR12 is similar). Furthermore, continuous variables can be replaced by categorical variables.

**Adherence**

Adherence will be displayed for the CP by genotype and cirrhosis status and for the SP by treatment regimen and cirrhosis status. Summary statistics (n, mean, median, standard deviation [SD], and range) will be generated for continuous variables. Numbers and percentages of patients will be presented for categorical variables.

- Adherence to ABBVIE regimen (% of target dose \[adherence=\text{cumulated number of pills taken} / (\text{initial prescribed number of pills x planned duration})\])
  - >105%
  - >95%\(\leq\)105%
  - >80%\(\leq\)95%
  - >50%\(\leq\)80%
  - \(\leq\)50%

- Adherence to ribavirin (% of target dose \[adherence=\text{cumulated dose taken} / (\text{initial prescribed dose x planned duration})\])
• Percentage of actual treatment duration in relation to the target duration of ABBVIE regimen taken
  - >105%
  - >95%-<=105%
  - >80%-<=95%
  - >50%-<=80%
  - <=50%

• Deviating duration of ABBVIE regimen
  - Early discontinuation (actual duration is shortened for more than 7 days)
  - Not deviated
  - Exceedance (actual duration is prolonged for more than 7 days)

• Method used to document adherence (Interview, Diary)

• Percentage of actual days with treatment with RBV in relation to the planned duration

• Ribavirin earlier discontinued than ABBVIE regimen

• Initial dose of Ribavirin
  - 1000 mg/day
  - 1200 mg/day
  - XXX

• Cumulative dose of Ribavirin (g)

• Dose modifications/termination of RBV [in patients taking RBV, for a patient more than one dose modification and its main reason could be reported, but for each single reason the patient is counted only once] (Total number of patients with lower dose than highest previous dose [including patients who stopped the treatment earlier], Anemia, Nausea/Vomiting, Rash, Other [including patients who discontinued ABBVIE regimen earlier, but did not stop the RBV treatment before the ABBVIE regimen])

In addition to the summary statistics of the adherence variables, logistic regression analyses will be performed for the following adherence variables: “adherence to ABBVIE regimen” in all patients of the CP, “adherence to ribavirin” in all patients of the CP taking RBV, each categorized as follows: >=95%, >80%-<=95%, <=80% to investigate the additional impact of overall treatment adherence on SVR12. The categories may be changed if they are sparsely filled. Adherence will be included as mandatory covariate in addition to the baseline explanatory variables already mentioned above. Also the same methods will be applied as described above.

An overview of Tables is given in Table 9.
### Table 8 Overview of Outputs for Primary and Secondary Effectiveness Analysis

<table>
<thead>
<tr>
<th>Output Title</th>
<th>Output Short Name</th>
<th>Analysis Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virological Response Rates by Genotype and Cirrhosis Status – CP/CPSFU - &lt;country&gt;</td>
<td>tvr_&lt;c&gt;_gc_cp</td>
<td>Core population/ Core population with sufficient follow-up data</td>
</tr>
<tr>
<td>Virological Response Rates by Genotype and Cirrhosis Status in Patients who Completed ABBVIE Regimen – CP/CPSFU - &lt;country&gt;</td>
<td>tvr_&lt;c&gt;_gc_cp_ARC</td>
<td>Core population/ Core population with sufficient follow-up data: patients who completed ABBVIE regimen</td>
</tr>
<tr>
<td>Virological Response Rates - NCP - &lt;country&gt;</td>
<td>tvr_&lt;c&gt;_ncp</td>
<td>Non-core population</td>
</tr>
<tr>
<td>Relapse Rates by Genotype and Cirrhosis Status – CP - &lt;country&gt;</td>
<td>trr_&lt;c&gt;_gc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Viral Breakthrough by Genotype and Cirrhosis Status – CP - &lt;country&gt;</td>
<td>tvb_&lt;c&gt;_gc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Non-Response Rates by Genotype and Cirrhosis Status – CP - &lt;country&gt;</td>
<td>tnrr_&lt;c&gt;_gc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Non-Response Rates by Genotype and Cirrhosis Status in Patients who Completed ABBVIE Regimen – CP - &lt;country&gt;</td>
<td>tnrr_&lt;c&gt;_gc_cp_ARC</td>
<td>Core population: patients who completed ABBVIE regimen</td>
</tr>
<tr>
<td>Impact of Patient and Disease Characteristics on SVR12 – CP - &lt;country&gt;</td>
<td>tis_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Adherence by Genotype and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>tah_&lt;c&gt;_gc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Adherence by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tah_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
</tr>
<tr>
<td>Impact of Adherence to ABBVIE Regimen on SVR12 – CP - &lt;country&gt;</td>
<td>tiaa_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Impact of Adherence to Ribavirin on SVR12 in patients taking RBV – CP - &lt;country&gt;</td>
<td>tiar_&lt;c&gt;_cp_RBV</td>
<td>Core population: patients taking RBV</td>
</tr>
</tbody>
</table>

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

### 4.2.7.2.2 Liver Fibrosis Assessment, Co-morbidities and co-infections

Liver fibrosis assessment will be summarized by visit in a table for CP by genotype and cirrhosis status and for the SP by treatment regimen and cirrhosis status displaying:

- Most recent stage of liver fibrosis (No cirrhosis, Transition to cirrhosis, Cirrhosis)
• Assessment method for liver fibrosis staging (Biopsy, Non-invasive, Clinical/Best guess)
• Time between biopsy assessment and treatment start [months] (continuous)
• Time between biopsy assessment and treatment end [months] (continuous)
• Metavir fibrosis score (0, 1, 2, 3, 4)
• Ishak fibrosis score (0, 1, 2, 3, 4, 5, 6)
• Batts/Ludwig fibrosis score (0, 1, 2, 3, 4)
• Knodell fibrosis score (0, 1, 3, 4)
• Scheuer fibrosis score (0, 1, 2, 3, 4)
• Time between FibroScan assessment and treatment start [months] (continuous)
• Time between FibroScan assessment and treatment end [months] (continuous)
• FibroScan [kPa] (<8.8, 8.8-<9.6, 9.6-<14.6, ≥14.6)
• Time between ARFI assessment and treatment start [months] (continuous)
• Time between ARFI assessment and treatment end [months] (continuous)
• AFRI [m/s]
• Time between FibroTest assessment and treatment start [months] (continuous)
• Time between FibroTest assessment and treatment end [months] (continuous)
• Results of FibroTest (<=0.21, 0.22-0.27, 0.28-0.31, 0.32-0.48, 0.49-0.58, 0.59-0.72, 0.73-0.74, ≥0.75)
• Esophageal varices (Yes, No, Unknown)
• Child Pugh Score (categorized as 5-6, 7-9, 10-15)

4.2.7.2.3 Quality of life
Quality of life will be analyzed for CP by cirrhosis status (cirrhosis vs transition to cirrhosis/no cirrhosis) and treatment regimen (2DAA w/o RBV, 2DAA + RBV, 3DAA w/o RBV and 3DAA + RBV).

Pictorial Representation of Illness and Self-Measure (PRISM)

The burden of suffering can be evaluated by using PRISM (Pictorial Representation of Illness and Self-Measure), which is a brief quantitative method to assess the perceived burden of suffering due to illness. The PRISM tool consists of an A4-size metal board, which stands for the patient’s life and a yellow disk, representing the patient, is fixed at the bottom right-hand corner. The patient is asked to reflect the importance of the illness in his/her life by placing a red disk, which represents his/her illness, on the metal board. The distance between the center of the “self” and the illness disc is called “self-illness separation” SIS and is measured in cm (range is 0-27).

A summary table will show descriptive statistics (n, mean, median, SD, minimum and maximum) for the SIS for baseline and the post-baseline time points, as well as changes from baseline, by cirrhosis status and treatment regimen. In addition, analysis of covariance (ANCOVA) will be applied to investigate the effect of the different ABBVIE REGIMENS (± RBV) by cirrhosis status on SIS using the corresponding SIS baseline values as covariates.

Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

The FACIT Measurement System is a collection of QOL questionnaires targeted to the management of chronic illness. Here, the FACIT-Fatigue will be considered.
The FACIT-Fatigue Scale is based on thirteen 5-level items (0="Not at all" to 4 = "Very much") measuring the level of fatigue over the past 7 days. Its 13-item-version assesses peripheral, central, or mixed fatigue and yields a summed total score ranging between 0 and 52. FACIT-Fatigue will be normed to 0-100. Higher FACIT-Fatigue scores indicate a lesser degree of fatigue. Notice that item 7 (I have energy) and item 8 (I am able to do my usual activities) are reversed scored. If a respondent answers at least 50% of the items of the FACIT-Fatigue questionnaire, the total score will be imputed with the average score of the answered items in the same scale as long as more than 50% (≥ 7 out of 13) of the items in the scale are answered.

A summary table will show descriptive statistics (n, mean, median, SD, minimum and maximum) for the total scores and for the subscales for baseline and the post-baseline time points, as well as changes from baseline, by cirrhosis status and treatment regimen. In addition, analysis of covariance (ANCOVA) will be applied to investigate the effect of the different ABBVIE REGIMENS (± RBV) by cirrhosis status on FACIT-Fatigue endpoints using the corresponding FACIT-Fatigue baseline values as covariates.

Assessment of work productivity and activity impairment – WPAI Hep C V2.0

The WPAI questionnaire will be used to measure work absenteeism, work presenteeism, and daily activity impairment. The WPAI Hep C V2.0 is the HCV specific questionnaire that will be used in this study. Respondents are asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity:

- % Presenteeism – percentage of impairment while working due to health problem
- % Absenteeism – percentage of work time missed due to health problem
- % Total work productivity impairment (TWP) – percentage of overall work impairment due to health problem
- % Total activity impairment (TAI) – percentage of general (non-work) activity impairment due to health problem

The WPAI Hep C v2.0 consists of 6 questions aimed at the following targets:

Q1.currently employed (yes, no)
Q2.hours missed due to hepatitis C in the last seven days
Q3.hours missed due to other reasons in the last seven days
Q4.hours actually worked in the last seven days
Q5.degree hepatitis C affected productivity while working
Q6.degree hepatitis C affected regular activities

The four scores will be derived according to the WPAI-SHP scoring manual [4] as follows:
1. % absenteeism: 100*Q2/(Q2+Q4)
2. % presenteeism: 100*Q5/10
3. % TWP: 100*(Q2/(Q2+Q4) + [Q4/(Q2+Q4)]* Q5/10)
4. % TAI: 100*Q6/10
The coding rules for contradictory or missing information are:

- If Q1 = YES or Q1 = NO or missing and hours missed or worked > 0, then employed. If Q1 = missing and hours missed and worked = 0, then not employed.
- If hours worked = 0, then productivity while at work is not applicable.
- A score will be set to missing if one or more of the items Q1-6 that are needed for the calculation of the score are missing. No imputation will be performed for missing items.
- Someone who missed all work hours due to health is 100% impaired.

The summary table will present the absolute and relative frequencies of employed and unemployed patients and descriptive statistics (n, mean, median, SD, minimum and maximum) for the four scores for baseline and the post-baseline time points by cirrhosis status and treatment regimen.

4.2.7.2.4 Attitude towards self-management, medication and support

The attitude towards self-management, medication and support will be analyzed for the CP.

**Patient Activation Measure – (PAM-13)**

The Patient Activation Measure (PAM) 13 is a measure used to assess the patient knowledge, skill, and confidence for self-management [5]. The PAM-13 item scale is a measure used to assess the patient knowledge, skill, and confidence for self-management. Each of the 13 items can be answered with one of four possible response options, which are “disagree strongly” (1), “disagree” (2), “agree” (3), “agree strongly” (4).

The scoring will be done by Insignia Health. If there are less than nine items answered, no summary score will be calculated.

A summary table will show descriptive statistics (n, mean, median, SD, minimum and maximum) of the score for baseline and the post-baseline time points, as well as changes from baseline, by cirrhosis status and treatment regimen. In addition, analysis of covariance (ANCOVA) will be applied to investigate the effect of the different ABBVIE REGIMENS (± RBV) by cirrhosis status on the score using the corresponding baseline value as covariate.
Table 9  Overview of Outputs for Secondary Variables

<table>
<thead>
<tr>
<th>Output Title</th>
<th>Output Short Name</th>
<th>Analysis Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver Fibrosis Assessment Results by Genotype and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>tfa_&lt;c&gt;_gc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Liver Fibrosis Assessment Results by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tfa_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
</tr>
<tr>
<td>PRISM by Treatment Regimen and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>tsis&lt;a&gt;_&lt;c&gt;_tc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>FACIT-Fatigue by Treatment Regimen and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>tfa&lt;a&gt;_&lt;c&gt;_tc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>WPAI by Treatment Regimen and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>twp_&lt;c&gt;_tc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>PAM-13 by Treatment Regimen and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>tpam&lt;a&gt;_&lt;c&gt;_tc_cp</td>
<td>Core population</td>
</tr>
</tbody>
</table>

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.8 Analyses of Safety

All safety variables will be summarized for patients in the SP using descriptive statistical methods stratified by treatment regimen and cirrhosis status and overall.

An overview of tables for the individual values is given in Table 13.

The layouts of the tables mentioned above are provided in Part II of the SAP (Table Shells).

4.2.8.1 Exposure to Study Medication

One table will show the frequencies for early discontinuation and exceedance of ABBVIE regimen or ribavirin and the corresponding reasons for SP by treatment regimen and cirrhosis status. The ABBVIE regimen is considered to have been prematurely discontinued if actual duration is shortened for more than 7 days. The duration for taking ABBVIE regimen is considered to have been exceeded if the actual duration is prolonged for more than 7 days. Furthermore, summary statistics will be generated for the duration of ABBVIE regimen taken and the duration of ribavirin taken, i.e. n, mean, median, standard deviation [SD], minimum, maximum.

Unintended medication errors, i.e. patient missed taking Paritaprevir/r-Ombitasvir or Dasabuvir for at least 7 days in a row, will be displayed by medication for the entire treatment period.
4.2.8.2 Co-medication

Treatments, surgical and medical procedures will be coded by ABBVIE assigning appropriate preferred and class terms. Frequencies will be displayed for SP by treatment regimen and cirrhosis status.

In one table, the co-medication (preferred term) will be grouped by class. Only co-medication received during treatment specified by ABBVIE regimen will be displayed (Treatment profiles: A1, A2, C1 Drug B, C2 Drug B, C3 Drug B, D).

In another table, the co-medication (preferred term) will be grouped by profile. All treatment profiles will be considered, i.e.:

- A1: Continued (A1)
- A2: Permanently discontinued during CHC treatment (A2)
- A3: Permanently discontinued prior to CHC treatment (A3)
- B: Discontinued prior to CHC treatment and reinduced post-treatment (B)
- C1 Drug A: Permanently replaced at start of CHC treatment (C1A)
- C1 Drug B: Substitute at start of CHC treatment and discontinued during CHC treatment (C1B)
- C2 Drug A: Permanently replaced at start of CHC treatment (C2A)
- C2 Drug B: Substitute at start of CHC treatment and continued (C2B)
- C3 Drug A: Replaced during CHC treatment (C3A)
- C3 Drug B: Substitute during CHC treatment (C3B)
- D: Introduced during CHC treatment (D)
- No profile reported: No profile reported

Another table will show the associated treatment profiles for the medications of special interest. Therefore the medication will be pooled appropriately. All treatment profiles will be considered.

A further table will show the associated treated conditions, i.e.:

- Alcoholic liver disease
- Angina pectoris
- Auto-immune hepatitis
- Auto-immune skin disease
- Bipolar disorder
- Chronic kidney disease
- Cryoglobulinemia
- Depression
- Diabetes mellitus (Type 1)
- Diabetes mellitus (Type 2)
- Hemophilia
- Hepatitis B
- Hepatocellular carcinoma
- HIV
- Hypertension
- Hyperthyroidism
- Hypothyroidism
- Immunologically mediated disease
- Insulin resistance
- Kidney transplantation
- Lipid disorder
- Liver transplantation
- Metabolic syndrome
- Myocardial infarction
- Opiate substitution
- Personality disorder
- Porphyria cutanea tarda (PCT)
- Primary biliary cirrhosis
- Schistosomiasis
- Schizophrenia
- Sickle cell anemia
- Steatosis (non-alcoholic)
- Stroke
- Thalassemia
- Tuberculosis
- v. Willebrand disease
- Wilson disease
- Other

All treatment profiles will be considered.

One table will displays the number of patients taking herbals except St. John's Wort, homeopathics or other drugs for which neither a name nor a profile nor a treated condition had to be reported. These medications will be excluded from the other co-medication tables.

A glossary will show the verbatim terms and the corresponding coded terms used (see Table 13).

4.2.8.3 Adverse Events

All tolerability variables will be summarized using descriptive statistical methods for the SP stratified by treatment regimen and cirrhosis status and overall.

AEs will be coded using MedDRA. A glossary will show the verbatim terms and the corresponding coded terms used (see Table 13).

The number and percentage of patients with treatment-emergent AEs (i.e. any reported event that begins or worsens in severity after initiation of study drug through 30 days post-study drug dosing including those who are related to the study drug independent of the occurrence and those where the date of onset is missing) will be tabulated by primary MedDRA SOC and PT.

Corresponding summary tables will be provided for all serious treatment-emergent AEs and additional for all non-serious treatment-emergent AEs. In the table of non-serious AEs (that must exclude any SAE) only preferred terms that occurred at a frequency of >=5% in any treatment group will be displayed (no SOCs will be displayed).

The tabulation of the number of patients with treatment-emergent AEs by severity (AEs by severity [mild, moderate, severe], AEs leading to death, AEs leading to hospitalization) and relationship to study drug will also be provided (ABBVIE regimen, ribavirin, medication error -
paritaprevir/r-ombitasvir, medication error – dasabuvir, ABBVIE regimen withdrawn, ribavirin withdrawn).

Patients reporting more than one AE for a given MedDRA PT will be counted only once for that term using the most severe incident for the severity summary table and the most related for the relationship summary table. Patients reporting more than one type of event within a SOC will be counted only once for that SOC.

The frequency of pregnancies will be displayed as well.

4.2.8.4 Laboratory Data

All reported clinical laboratory test results will be assigned to one of the time points using the time windows specified in the Table 5. All will be performed for the SP by treatment regimen and cirrhosis status.

Changes from baseline to each post-baseline visit will be summarized descriptively (N, mean, SD, median, minimum, maximum). A summary table will show laboratory hematology. In another table information about clinical chemistry will be summarized.

In a further table CD4 and HIV-RNA are displayed for patients with HIV only by visit.

Instead of the shift tables mentioned in the study protocol, the number and percentage of subjects with post-baseline values until EoT meeting the specified criteria for Potentially Clinically Significant (PCS) laboratory values (defined in Table 11) will be summarized. A post-baseline value must be more extreme than the baseline value to be considered a PCS finding.
Table 10 Criteria for PCS laboratory values

<table>
<thead>
<tr>
<th>Laboratory data</th>
<th>Very Low</th>
<th>Very High</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Laboratory hematology</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin [g/L]</td>
<td>&lt;80</td>
<td></td>
</tr>
<tr>
<td>Platelets [10^9/L]</td>
<td>&lt;50</td>
<td></td>
</tr>
<tr>
<td><strong>Laboratory clinical chemistry</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT</td>
<td>&gt;5 x ULN and &gt;= 2 x baseline</td>
<td></td>
</tr>
<tr>
<td>AST</td>
<td>&gt;5 x ULN and &gt;= 2 x baseline</td>
<td></td>
</tr>
<tr>
<td>Creatinine [μmol/L]</td>
<td>&gt;132.605</td>
<td></td>
</tr>
<tr>
<td>Creatinine clearance [mL/min]**</td>
<td>&lt;50</td>
<td></td>
</tr>
</tbody>
</table>

**estimated by Cockcroft-Gault-Formula (see above)**

Additionally, for hemoglobin and creatinine clearance, the number and percentage of subjects with a maximum Common Terminology Criteria for Adverse Events (CTCAE) Grade of 0, 1, 2, 3, or 4 (see definitions in Table 12) at any post-baseline visit (regardless of the baseline value) through the end of treatment (i.e., Final Treatment Value) will be summarized. For the liver function tests (LFTs) of ALT and AST, the number and percentage of subjects in with a maximum CTCAE Grade of 0, 1, 2, 3, or 4 (see definitions in Table 12) at any post-nadir visit through the end of treatment (i.e., Final Treatment Value) will be summarized. Note, for these analyses, the nadir is used for reference (including baseline).

Table 11 Definition of CTCAE Grades 0-4

<table>
<thead>
<tr>
<th>Laboratory data</th>
<th>Grade 0</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT</td>
<td>&lt;=ULN</td>
<td>&gt;ULN – 3 x ULN</td>
<td>&gt; 3 – 5 x ULN</td>
<td>&gt; 5 – 20 x ULN</td>
<td>&gt; 20 x ULN</td>
</tr>
<tr>
<td>AST</td>
<td>&lt;=ULN</td>
<td>&gt;ULN – 3 x ULN</td>
<td>&gt; 3 – 5 x ULN</td>
<td>&gt; 5 – 20 x ULN</td>
<td>&gt; 20 x ULN</td>
</tr>
<tr>
<td>Hemoglobin Decreased [g/L]</td>
<td>&gt;=130</td>
<td>&lt;130 – 100</td>
<td>&lt; 100 - 80</td>
<td>&lt; 80 - 65</td>
<td>&lt; 65</td>
</tr>
<tr>
<td>Creatinine Clearance [mL/min]</td>
<td>&gt;= 75</td>
<td>&lt; 75 - 60</td>
<td>&lt; 60 - 30</td>
<td>&lt; 30 – 15</td>
<td>&lt; 15</td>
</tr>
<tr>
<td>Output Title</td>
<td>Output Short Name</td>
<td>Analysis Population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exposure to Study Medication by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>testsm_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unintended Medication Error/ Pregnancy by Treatment Regimen and Cirrhosis Status -- SP - &lt;country&gt;</td>
<td>tum_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment-emergent AEs by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tae_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serious Treatment-emergent AEs by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tsae_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Serious Treatment-emergent AEs by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tnsae_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment-emergent AEs by Severity by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>taes_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment-emergent AEs Leading to Death by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>taed_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment-emergent AEs Leading to Hospitalization by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>taeh_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment-emergent AEs Possibly Related to ABBVIE Regimen by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>taera_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment-emergent AEs Possibly Related to Ribavirin in Patients taking RBV by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>taerr_&lt;c&gt;_tc_sp_RB_V</td>
<td>Safety population: patients taking RBV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment-emergent AEs Caused by Medication Error - Paritaprevir/Ombitasvir by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>taempo_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment-emergent AEs Caused by Medication Error - Dasabuvir in Patients taking 3DAA by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>taemd_&lt;c&gt;_tc_sp_3d_aa</td>
<td>Safety population: patients taking 3DAA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment-emergent AEs Leading to Withdrawal of ABBVIE Regimen by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>taewa_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment-emergent AEs Leading to Withdrawal of Ribavirin in Patients taking RBV by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>taewr_&lt;c&gt;_tc_sp_RB_V</td>
<td>Safety population: patients taking RBV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Listing of SAEs - SP - &lt;country&gt;</td>
<td>lsae_&lt;c&gt;_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glossary for AEs - &lt;country&gt;</td>
<td>tgae_&lt;c&gt;</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-medication by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tcom_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-medication by Profile and by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tcomp_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Associated Treated Condition by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tatc_&lt;c&gt;_tc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Associated Treatment Profiles by Medication of Special Interest and by Treatment Regimen and Cirrhosis Status - SP - &lt;country&gt;</td>
<td>tatp_&lt;c&gt;_mtc_sp</td>
<td>Safety population</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
4.2.9  **Interim Analyses**

4.2.9.1  **First Interim Analysis**

The first interim analysis (IA) was performed in May 2016 (data snapshot: 2 May 2016).

Site information and researcher experience were displayed, as well as patient disposition by genotype and cirrhosis status for the EP.

The CP was restricted to patients with planned treatment duration of 12 weeks who started DAA treatment before 1st April 2016. The following tables were created for the CP:

- treatment regimen
- socio-demographic characteristics
- CHC disease characteristics
- CHC Related laboratory variables at baseline
- other key laboratory variables at baseline
- CHC treatment history in treatment experienced patients
- Co-morbidities and co-infections
- alcohol consumption
- CD4 and HIV-RNA in patients with HIV at baseline

All tables were structured by genotype and cirrhosis status. Additionally to the tables above the patient-reported outcomes at baseline were displayed by genotype and cirrhosis status for the CP (i.e. FACIT Fatigue Subscale Score (not normed), PAM-13: Total Score, PAM-13: Level, WPAI: Employment Status, WPAI: Absenteeism (%), WPAI: Presenteeism (%), WPAI: Total Work Productivity Impairment (%), WPAI: Total Activity Impairment (%), PRISM: Self-Illness-separation [cm])
Furthermore ANOVAs were conducted in addition to descriptive statistics (i.e. mean, median, SD, SE, 95%CI of the mean) to describe the association between disease characteristics and SIS (PRISM) for categorial variables. The following disease characteristics were considered: sex, age (18-65 years, 66-84 years), race / ethnic origin (White/Caucasian, Asian/Oriental), BMI [kg/sqm] (<25, 25-<30, >=30), HCV genotype (G1/G4), HCV RNA [IU/mL] (800,000,>=800,000), mode of HCV infection (drug use [i.v./non i.v.], blood transfusion or transplantation, unknown, other [all other modes]), years since diagnosis of HCV infection (<5, 6-10,11-15,>=16), cirrhosis status at BL (yes/no), HCV Co-infection, liver and/or CHC related co-morbidities, other co-morbidities. (For co-morbidities categories the following definition was used: Patients not selecting at least one of the subcategories of the respective category were considered as not having this co-morbidity category.)

For continuous variables scatterplots were created with a linear fit. Additionally, R², the Spearman correlation coefficient and the Pearson correlation coefficient were displayed. The following disease characteristics were considered: Correlation between PRISM and age, BMI, viral load, years since diagnosis of HCV infection, FACIT fatigue subscale score (not normed), WPAI absenteeism, WPAI presenteeism, WPAI total work productivity impairment, WPAI total activity impairment, PAM13.

4.2.9.2 Second Interim Analysis

A second IA was performed in October 2016 (data snapshot: 5 October 2016). The first IA was updated. Furthermore, the following analyses were performed:

Site information and researcher experience were displayed, as well as patient disposition by genotype and cirrhosis status for the EP.

The CP and SP were restricted to patients with planned treatment duration of 12 weeks who started DAA treatment before 1st April 2016.

The following tables were created for the restricted CP:

- treatment regimen
- socio-demographic characteristics
- CHC disease characteristics
- CHC Related laboratory variables at baseline
- other key laboratory variables at baseline
- CHC treatment history in treatment experienced patients
- Co-morbidities and co-infections
- alcohol consumption
- CD4 and HIV-RNA in patients with HIV at baseline
- PRISM, FACIT Fatigue Subscale Score (not normed), WPAI, PAM13 over time
- Premature Termination of Treatment and its Main Reason
- Virological Response Rates (Virological response rates will be displayed in the CPSFU12 and in patients with an evaluable HCV RNA test result as well.)

All tables were structured by genotype and cirrhosis status, except for the analyses regarding questionnaires. These analyses were structured by treatment regimen and cirrhosis status.
Additionally, the impact of various explanatory covariates (patient and disease characteristics) at baseline on SVR12 was analyzed. Opiate substitution was added as additional covariate and age will be categorized (>= 70/< 70 years) here. (No interaction was taken into account.)

For the restricted SP the following tables will be created:

- Treatment-emergent AEs
- Serious Treatment-emergent AEs

The tables will be structured by treatment regimen and cirrhosis status.

The analyses were repeated replacing cirrhosis status once by age (>= 70/< 70 years) and once by opiate substitution (no/yes; yes, is defined as patients with psychoactive substance dependency - opiate substitution)

### 4.2.9.3 Third Interim Analysis

A third IA was performed in January 2017 (data snapshot: 16 January 2017) and was updated in March 2017 (data snapshot: 20 March 2017).

Site information and researcher experience were displayed, as well as patient disposition by genotype and cirrhosis status for the EP.

The following tables were created for the CP:

- treatment regimen
- premature termination of treatment and its main reason
- socio-demographic characteristics
- CHC disease characteristics
- CHC Related laboratory variables at baseline
- other key laboratory variables at baseline
- CHC treatment history in treatment experienced patients
- Co-morbidities and co-infections
- alcohol consumption
- CD4 and HIV-RNA in patients with HIV at baseline
- PROs at baseline (i.e. FACIT Fatigue Subscale Score (not normed), PAM-13: Total Score, PAM-13: Level, WPAI: Employment Status, WPAI: Absenteeism (%), WPAI: Presenteeism (%), WPAI: Total Work Productivity Impairment (%), WPAI: Total Activity Impairment (%), PRISM: Self-illness-separation [cm])

All tables were structured by genotype and cirrhosis status. The analyses were repeated replacing cirrhosis status once by age (>= 70/< 70 years) and once by opiate substitution (no/yes; yes, is defined as patients with psychoactive substance dependency - opiate substitution).

Furthermore ANOVAs were conducted in addition to descriptive statistics (i.e. mean, median, SD, SE, 95%CI of the mean) to describe the association between disease characteristics and SIS (PRISM) for categorical variables. The following disease characteristics were considered: sex, age (18-69 years, >=70 years), race / ethnic origin (White/Caucasian, Asian/Oriental), BMI [kg/sqm] (<25, 25-<30, >=30), HCV genotype (G1/G4), HCV RNA [IU/mL] (800,000,>=800,000), mode of HCV infection (drug use [i.v./non i.v.], blood transfusion or transplantation, unknown, sexual transmission, blood transfusion or transplantation, other [all other modes]), years since diagnosis.
of HCV infection (<=5, 6-10, 11-15, >=16), cirrhosis status at BL (yes/no), HCV Co-infection, liver and/or CHC related co-morbidities, other co-morbidities, opiate substitution. (For co-morbidities categories the following definition was used: Patients not selecting at least one of the subcategories of the respective category were considered as not having this co-morbidity category.)

Furthermore, the CP and SP were restricted to patients with planned treatment duration of 12 weeks who started DAA treatment before 1st July 2016.

The following tables were created for the restricted CP:

- treatment regimen
- Premature Termination of Treatment and its Main Reason
- socio-demographic characteristics
- CHC disease characteristics
- CHC Related laboratory variables at baseline
- other key laboratory variables at baseline
- CHC treatment history in treatment experienced patients
- Co-morbidities and co-infections
- alcohol consumption
- CD4 and HIV-RNA in patients with HIV at baseline
- Adherence
- Virological response rates (once in all patients and once in patients who completed AbbVie regimen)
- Relapse rates
- Viral breakthrough
- PRISM, FACIT Fatigue Subscale Score (not normed), WPAI, PAM13 over time

Non-response rates were displayed for the CPSFU12 (once in all patients and once in patients who completed AbbVie regimen). All tables were structured by genotype and cirrhosis status, except for the analyses regarding questionnaires. These analyses were structured by treatment regimen and cirrhosis status. The analyses were repeated replacing cirrhosis status once by age (>= 70/< 70 years) and once by opiate substitution (no/yes; yes, is defined as patients with psychoactive substance dependency - opiate substitution).

Additionally, the impact of various explanatory covariates (patient and disease characteristics) at baseline on SVR12 was analyzed. Opiate substitution was added as additional covariate and age will be categorized (>= 70/< 70 years) here.

For the SP the following tables were created:

- Exposure to study medication
- Treatment-emergent AEs
- Serious treatment-emergent AEs
- Co-medication
- Laboratory hematology
- Laboratory clinical chemistry
- Potentially clinically significant laboratory values
• Worst laboratory values

The tables were structured by treatment regimen and cirrhosis status. The analyses were repeated replacing cirrhosis status once by age (>= 70/< 70 years) and once by opiate substitution (no/yes; yes, is defined as patients with psychoactive substance dependency - opiate substitution).

4.2.9.4 Fourth Interim Analysis

A fourth IA was performed in August 2017 (data snapshot: 21 August 2017).

Site information and researcher experience were displayed, as well as patient disposition by genotype and cirrhosis status for the EP.

The following tables were created for the CP:

• treatment regimen
• premature termination of treatment and its main reason
• socio-demographic characteristics
• CHC disease characteristics
• CHC Related laboratory variables at baseline
• other key laboratory variables at baseline
• CHC treatment history in treatment experienced patients
• Co-morbidities and co-infections
• alcohol consumption
• CD4 and HIV-RNA in patients with HIV at baseline
• Adherence
• Virological response rates (once in all patients and once in patients who completed AbbVie regimen)
• Relapse rates
• Viral breakthrough
• PRISM, FACIT Fatigue Subscale Score (not normed), WPAI, PAM13 over time (including pre-post comparisons)

Non-response rates were displayed for the CPSFU12 (once in all patients and once in patients who completed AbbVie regimen). All tables were structured by genotype and cirrhosis status, except for the analyses regarding questionnaires. These analyses were structured by treatment regimen and cirrhosis status. The analyses were repeated replacing cirrhosis status once by age (>= 70/< 70 years) and once by opiate substitution (no/yes; yes, is defined as patients with psychoactive substance dependency - opiate substitution).

Furthermore ANOVAs were conducted in addition to descriptive statistics (i.e. mean, median, SD, SE, 95%CI of the mean) to describe the association between disease characteristics and SIS (PRISM) for categorial variables. The following disease characteristics were considered: sex, age (18-69 years, >=70 years), race / ethnic origin (White/Caucasian, Asian/Oriental), BMI [kg/sqm] (<25, 25-<30, >=30), HCV genotype (G1/G4), HCV RNA [IU/mL] (800,000,>=800,000), mode of HCV infection [drug use [i.v./non i.v.], blood transfusion or transplantation, unknown, sexual transmission, blood transfusion or transplantation, other [all other modes]), years since diagnosis of HCV infection (<=5, 6-10.11-15,>=16), cirrhosis status at BL (yes/no), HCV Co-infection, liver and/or CHC related co-morbidities, other co-morbidities, opiate substitution. (For co-morbidities
categories the following definition was used: Patients not selecting at least one of the subcategories of the respective category were considered as not having this co-morbidity category.)

Additionally, the impact of various explanatory covariates (patient and disease characteristics) at baseline on SVR12 was analyzed. Opiate substitution was added as additional covariate and age will be categorized (>= 70/< 70 years) here.

For the SP the following tables will be created:

- Exposure to study medication
- Treatment-emergent AEs
- Serious treatment-emergent AEs
- Co-medication
- Laboratory hematology
- Laboratory clinical chemistry
- Potentially clinically significant laboratory values
- Worst laboratory values
- Herbals Except St. John's Wort, Homeopathics or Other Drugs Taken During Study

The tables were structured by treatment regimen and cirrhosis status. The analyses were repeated replacing cirrhosis status once by age (>= 70/< 70 years) and once by opiate substitution (no/yes; yes, is defined as patients with psychoactive substance dependency - opiate substitution).

As supplementary analyses, the questionnaire scores were compared for the OST groups and once for the RBV groups by OST groups. (FACIT-Fatigue was normed to 0-100 for these analyses.) In addition, the interaction between RBV and OST on questionnaire scores was analyzed. Furthermore the analyses regarding FACIT-Fatigue mentioned above were repeated using the new scale.

### 4.2.9.5 Fifth Interim Analysis

A fifth IA will be performed in December 2017/January 2018 (data snapshot: 18 December 2017).

Site information and researcher experience were displayed, as well as patient disposition by genotype and cirrhosis status for the EP.

The following tables were created for the CP:

- treatment regimen
- premature termination of treatment and its main reason
- socio-demographic characteristics
- CHC disease characteristics
- CHC Related laboratory variables at baseline
- other key laboratory variables at baseline
- CHC treatment history in treatment experienced patients
- Co-morbidities and co-infections
- alcohol consumption
- CD4 and HIV-RNA in patients with HIV at baseline
- Adherence
- Virological response rates (once in all patients and once in patients who completed AbbVie regimen)
- Relapse rates
- Viral breakthrough
- PRISM, FACIT Fatigue Subscale Score (normed), WPAI, PAM13 over time (including pre-post comparisons)

Non-response rates will be displayed for the CPSFU12 (once in all patients and once in patients who completed AbbVie regimen). All tables will be structured by genotype and opiate substitution (no/yes; yes, is defined as patients with psychoactive substance dependency - opiate substitution), except the tables for the questionnaires. The scores will once be compared for the OST groups and once for the RBV groups by OST groups. The interaction between OST and RBV intake will be analyzed as well.

Furthermore ANOVAs will be conducted in addition to descriptive statistics (i.e. mean, median, SD, SE, 95%CI of the mean) to describe the association between disease characteristics and SIS (PRISM) for categorial variables. The following disease characteristics will be considered: sex, age (18-69 years, >=70 years), race / ethnic origin (White/Caucasian, Asian/Oriental), BMI [kg/sqm] (<25, 25-<30, >=30), HCV genotype (G1/G4), HCV RNA [IU/mL] (800,000,>=800,000), mode of HCV infection (drug use [i.v./non i.v.], blood transfusion or transplantation, unknown, sexual transmission, blood transfusion or transplantation, other [all other modes]), years since diagnosis of HCV infection (<5, 6-10,11-15,>=16), cirrhosis status at BL (yes/no), HCV Co-infection, liver and/or CHC related co-morbidities, other co-morbidities, opiate substitution. (For co-morbidities categories the following definition will be used: Patients not selecting at least one of the subcategories of the respective category will be considered as not having this co-morbidity category.)

Additionally, the impact of various explanatory covariates (patient and disease characteristics) at baseline on SVR12 will be analyzed. Opiate substitution will be added as additional covariate and age will be categorized (>= 70/< 70 years) here.

For the SP the following tables will be created:
- Exposure to study medication
- Treatment-emergent AEs
- Serious treatment-emergent AEs
- Co-medication
- Laboratory hematology
- Laboratory clinical chemistry
- Potentially clinically significant laboratory values
- Worst laboratory values
- Herbals Except St. John's Wort, Homeopathics or Other Drugs Taken During Study

The tables were structured by treatment regimen and opiate substitution (no/yes; yes, is defined as patients with psychoactive substance dependency - opiate substitution).
### Table 13  Overview of Outputs for Interim Analyses

<table>
<thead>
<tr>
<th>Output Title</th>
<th>Output Short Name</th>
<th>Analysis Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient-reported outcomes at Baseline by Genotype and Cirrhosis Status - CP - &lt;country&gt;</td>
<td>tpro_&lt;c&gt;_gc_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Association between Patient and Disease Characteristics and SIS (PRISM) - CP - &lt;country&gt;</td>
<td>tpac_&lt;c&gt; _cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Correlation between PRISM and Age - CP - &lt;country&gt;</td>
<td>fCORR_PRISM_AGE _&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Correlation between PRISM and Body Mass index (BMI) - CP - &lt;country&gt;</td>
<td>fCORR_PRISM_BMI _&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Correlation between PRISM and Viral load - CP - &lt;country&gt;</td>
<td>fCORR_PRISM_PCR BL_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Correlation between PRISM and Years since diagnosis of HCV infection - CP - &lt;country&gt;</td>
<td>fCORR_PRISM_HCV DIAG_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Correlation between PRISM and FACIT Fatigue Subscale Score - CP - &lt;country&gt;</td>
<td>fCORR_PRISM_FAC IT_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Correlation between PRISM and WPAI Absenteeism - CP - &lt;country&gt;</td>
<td>fCORR_PRISM_WP ABS_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Correlation between PRISM and WPAI Presenteeism - CP - &lt;country&gt;</td>
<td>fCORR_PRISM_WP PRE_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Correlation between PRISM and WPAI Total Work Productivity Impairment - CP - &lt;country&gt;</td>
<td>fCORR_PRISM_WP TWP_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Correlation between PRISM and WPAI Total Activity Impairment - CP - &lt;country&gt;</td>
<td>fCORR_PRISM_WP TAI_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Correlation between PRISM and PAM13 - CP - &lt;country&gt;</td>
<td>fCORR_PRISM_PAM _&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>WPAI (Pre-Post-Change) by &lt;Cirrhosis Status/ Age /Opiate Substitution&gt;- CP - &lt;country&gt;</td>
<td>twpt_&lt;o/a3/c&gt;_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Interaction between RBV Intake and Opiate Substitution on PRISM - CP - &lt;country&gt;</td>
<td>tsisi_RBVo_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Interaction between RBV Intake and Opiate Substitution on FACIT Fatigue Subscale Score - CP - &lt;country&gt;</td>
<td>tfai_RBVo_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Interaction between RBV Intake and Opiate Substitution on WPAI - CP - &lt;country&gt;</td>
<td>twpi_RBVo_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
<tr>
<td>Interaction between RBV Intake and Opiate Substitution on PAM-13 - CP - &lt;country&gt;</td>
<td>tpami_RBVo_&lt;c&gt;_cp</td>
<td>Core population</td>
</tr>
</tbody>
</table>
4.2.10 Protocol Violations and Deviations
Enrolled patients who are excluded from the analysis populations will be summarized and the reasons listed (see section 4.2.1).

5 Data Quality Assurance
Data for this study will be recorded in English by each participating center via an electronic data capture (EDC) system using a web-based eCRF.

A comprehensive data validation program utilizing front-end checks in the eCRF will validate the data. Automated checks for data consistency will be implemented. Discrepancies need to be solved by the researcher in the eCRF before the module can be completed.

Follow-up on eCRF data for medical plausibility will be done by ABBVIE personnel (or their representatives). Queries will be generated in the eCRF for online resolution at the site. The investigator or an authorized member of the investigator's staff will make any necessary data corrections to the eCRF. All change information, including the date and person performing the corrections, will be available via the audit trail, which is part of the EDC system. The principal investigator of each site will finally review the eCRFs for completeness and accuracy of available data and provide his or her electronic signature and date to the eCRFs as evidence thereof.

All statistical programs employed in the analysis and reporting of the data will be validated according the standard operating procedures of IST and results will be checked for plausibility.

6 Methods of Data Analysis and Presentation
All statistical analyses will be carried out by means of the SAS® package (Version 9.4).

6.1 Analysis Data Sets
A value added dataset STRATIFY will be programmed. This will contain derived variables, e.g. analysis populations, treatment regimen and relevant baseline characteristics, needed for the generation of the planned analyses.

A value added dataset SITES will be programmed. This will contain site information and researcher experience needed for the generation of the planned analyses.

Additional value added dataset will be programmed for the primary and secondary endpoints.
6.2 SAS Output Format

Detailed descriptions of the SAS outputs are given in Part II of the SAP (Table Shells).

7 References


3. EQ-5D-5L User Guide; Basic information on how to use the EQ-5D-5L instrument. Prepared by Mandy Oemar / Bas Janssen. Version 2.0; October 2013

